US · SCYX
SCYNEXIS, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Jersey City, NJ 07302-6548
- Website
- scynexis.com
Price · as of 2024-12-31
$0.99
Market cap 31.47M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $52.30 | +5,181.23% |
| Intrinsic Value(DCF) | $0.60 | -39.41% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $37.31 | +3,667.95% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $99.50 | $150.77 | $27.59 | $21.65 | $601.41 |
| 2015 | $41.60 | $261.57 | $9.94 | $0.00 | $1,824.21 |
| 2016 | $26.80 | $18.55 | $3.13 | $0.00 | $0.00 |
| 2017 | $14.30 | $36.25 | $0.00 | $0.00 | $0.00 |
| 2018 | $12.20 | $18.07 | $0.00 | $0.00 | $0.00 |
| 2019 | $9.80 | $11.91 | $0.00 | $0.00 | $407.65 |
| 2020 | $8.54 | $20.80 | |||
| 2021 | $3.97 | $0.00 | $0.00 | ||
| 2022 | $1.33 | $24.58 | $0.00 | $0.00 | $74.58 |
| 2023 | $1.66 | $434.96 | $92.04 | $8.53 | $3,566.33 |
| 2024 | $0.97 | $52.30 | $0.37 | $0.00 | $37.31 |
AI valuation
Our deep-learning model estimates SCYNEXIS, Inc.'s (SCYX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $52.30
- Current price
- $0.99
- AI upside
- +5,181.23%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.60
-39.41% upside
Graham-Dodd
—
— upside
Graham Formula
$37.31
+3,667.95% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SCYX | SCYNEXIS, Inc. | $0.99 | 31.47M | +5,181% | -39% | — | +3,668% | -2.21 | 0.85 | 12.54 | -0.21 | — | 0.85 | 100.00% | -990.84% | -568.29% | -33.25% | -288.55% | -19.44% | 0.30 | -14.53 | 3.00 | 2.89 | -0.01 | -13165.00% | -9733.00% | -13991.00% | -51.13% | -1.00 | -186.64% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 1.05 | -5.70 |
| CLGN | CollPlant Biotechnologies… | $0.57 | 7.18M | +8,539% | +137% | — | +21,233% | -2.30 | 2.84 | 74.26 | -1.89 | -1.72 | 2.87 | -417.09% | -3349.71% | -3225.05% | -79.46% | -364.64% | -62.87% | 0.23 | -1014.76 | 4.44 | 4.21 | 0.57 | 13387.00% | -9530.00% | 29214.00% | -38.11% | -4.75 | -308.10% | 0.00% | 0.00% | 0.00% | -1.71 | -2.02 | 57.12 | -6.47 |
| COSM | Cosmos Health Inc. | $0.39 | 10.71M | +8,441% | +650% | — | — | -0.61 | 0.40 | 0.18 | -1.53 | — | 0.59 | 7.92% | -28.56% | -29.73% | -53.43% | -38.56% | -26.90% | 0.48 | -15.36 | 0.99 | 0.63 | -0.83 | -4558.00% | 197.00% | -6720.00% | -82.82% | -0.30 | -20.18% | 63.07% | -38.30% | 63.07% | -1.37 | -2.62 | 0.39 | -2.69 |
| CVKD | Cadrenal Therapeutics, In… | $8.49 | 19.85M | — | — | — | — | -1.93 | 2.76 | — | -0.99 | — | 2.76 | 0.00% | — | — | -140.78% | 670.96% | -114.27% | 0.00 | — | 3.77 | 3.75 | 0.94 | -935.00% | — | 10840.00% | -35.84% | -2.74 | 450.80% | 0.00% | 0.00% | 7.97% | -0.96 | -1.43 | — | -1.66 |
| KLTO | Klotho Neurosciences, Inc… | $0.53 | 28.02M | — | — | — | — | -0.90 | 4.69 | — | -1.00 | 0.00 | -4.99 | 0.00% | — | — | -700.07% | -323.09% | -264.53% | 0.23 | -15.54 | 0.13 | 0.05 | -0.04 | 4561429.00% | — | 56623.00% | -55.19% | -2.36 | -179.03% | 0.00% | 0.00% | 24.75% | -1.04 | -1.88 | — | -11.37 |
| NRSN | NeuroSense Therapeutics L… | $0.91 | 22.42M | — | — | — | — | -2.06 | 8.14 | — | -1.79 | — | 8.14 | 0.00% | — | — | -2880.11% | 388.77% | -263.45% | 0.03 | -31.84 | 2.21 | 1.78 | 0.33 | -3373.00% | — | 2094.00% | -48.23% | -5.09 | 398.04% | 0.00% | 0.00% | 3.84% | -1.79 | -1.75 | — | -11.40 |
| NXL | Nexalin Technology, Inc. | $0.47 | 8.77M | +5,717% | +102% | — | — | -2.88 | 5.97 | 130.00 | -2.38 | -9.08 | 6.42 | 78.31% | -4596.14% | -4508.73% | -221.05% | -3380.55% | -193.70% | 0.00 | — | 7.25 | 6.39 | 0.07 | 3175.00% | 5235.00% | -1.00% | -17.98% | -7.21 | -1719.51% | 0.00% | 0.00% | 0.00% | -2.38 | -4.68 | 109.37 | -9.04 |
| SONN | Sonnet BioTherapeutics Ho… | $1.26 | 8.43M | +87,488% | -33% | — | +67,885% | -0.19 | -2.83 | 73.88 | -0.12 | — | -2.83 | 100.00% | -63617.91% | -39929.30% | 2089.93% | 846.19% | -181.38% | -0.27 | — | 0.66 | 0.28 | 0.00 | -9218.00% | -8740.00% | -6049.00% | -625.56% | -2.68 | 614.69% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 72.88 | -73.78 |
| TLPH | Talphera, Inc. | $0.91 | 18.7M | +3,728% | — | — | — | -1.09 | 1.78 | — | -0.78 | — | 1.78 | 0.00% | — | — | -117.65% | -293.62% | -67.32% | 0.82 | -38.71 | 3.56 | 3.35 | 0.15 | -6124.00% | -10000.00% | -2790.00% | -89.22% | -4.79 | -244.16% | 0.00% | 0.00% | 0.00% | -0.78 | -0.94 | — | -36.58 |
| XCUR | Exicure, Inc. | $3.74 | 23.84M | — | +24% | — | — | -7.29 | 10.45 | 141.51 | -7.25 | — | 10.45 | 100.00% | -2446.40% | -1940.20% | -197.92% | -269.46% | -72.84% | 0.88 | -679.56 | 4.45 | 4.24 | 0.74 | -2464.00% | — | -7190.00% | -4.11% | -0.95 | -64.10% | 0.00% | 0.00% | 17.56% | -5.25 | -22.06 | 128.36 | -15.21 |
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
- CEO
- David Gonzalez Angulo
- Employees
- 28
- Beta
- 1.34
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.60 ÷ $0.99) − 1 = -39.41% (DCF, example).